Is the new treatment for aplastic anemia avatrombopag/sucoxin?

Aplastic anemia (Aplastic Anemia, AA) is a disease caused by insufficient blood cell production caused by a significant reduction in the number of bone marrow hematopoietic stem cells. The clinical manifestations are pancytopenia, including anemia, leukopenia and thrombocytopenia. Traditional treatments mainly include immunosuppressive therapy (IST), stem cell transplantation, and supportive care, but there are still problems with inconsistent efficacy or poor tolerability. Therefore, the exploration of new treatments has always been a hot spot in hematology research.

Avatrombopag is an oral thrombopoietin receptor agonist (TPO-RA) initially used to treat thrombocytopenia associated with chronic liver disease and immune thrombocytopenia (ITP). In recent years, clinical studies have shown that avatrombopag also shows certain efficacy in patients with aplastic anemia. Its mechanism of action is mainly through activating thrombopoietin (TPO) receptors to promote the proliferation and differentiation of bone marrow megakaryocytes, thereby indirectly increasing the level of platelet production. This mechanism makes it a new option for adjuvant treatment of AA, especially for patients who have insufficient response to immunosuppressive therapy or cannot tolerate traditional treatment.

Overseas research and practice have shown that avatrombopag can be used in combination with standard immunosuppressive therapy to improve platelet production. Some patients also experienced improvements in red blood cell and neutrophil levels after continued use, suggesting that it may have a certain promoting effect on overall hematopoiesis. The drug is an oral preparation, which is convenient for patients to use in the clinic or at home. At the same time, the efficacy and safety can be monitored through blood routine. Side effects include mild to moderate headache, fatigue and fluctuations in liver function indicators, so regular follow-up and hematology monitoring are required during medication.

In general, avatrombopag is regarded as a new treatment in aplastic anemia, mainly targeting insufficient platelet production, and can provide a complementary option to traditional treatment options. Although it is not the first-line standard therapy for AA, its unique mechanism of action and advantages of oral administration have attracted attention in clinical practice and provided new hope for patients who cannot tolerate or have poor response to traditional therapies.

Reference materials:https://go.drugbank.com/drugs/DB11995